Tirzepatide is a once-weekly injectable medication that activates two gut hormone receptors at once, GIP and GLP-1. It is the active molecule in Mounjaro and Zepbound. Compounded tirzepatide at Telos Rx is prescribed only after review by a licensed provider.
If searching "what is tirzepatide" left you in a maze of brand names, here is the plain version: what the molecule is, why "dual" keeps appearing, which brands contain it, and what the trials reported.
Tirzepatide, Mounjaro and Zepbound: One Molecule, Two Brands
These are not different drugs. Tirzepatide is the generic name. Mounjaro and Zepbound are two Eli Lilly brands built on that same molecule, approved for different conditions.
Mounjaro was approved in 2022 for type 2 diabetes. Zepbound followed in November 2023 for chronic weight management, adding obstructive sleep apnea in December 2024.
Compounded tirzepatide is a third category, and the one most often confused with the others. Same active molecule, but not FDA-approved, and prepared by licensed US compounding pharmacies against an individual prescription.
| Product | Active molecule | FDA status | Approved for |
|---|---|---|---|
| Mounjaro | Tirzepatide | FDA-approved (2022) | Type 2 diabetes |
| Zepbound | Tirzepatide | FDA-approved (2023) | Chronic weight management; obstructive sleep apnea with obesity (2024) |
| Compounded tirzepatide | Tirzepatide | Not FDA-approved | Prescribed individually by a licensed provider |
The overlap is unpacked in Is Mounjaro tirzepatide? and Is Zepbound the same as tirzepatide?
Is Tirzepatide a GLP-1? Yes, Plus a Second Receptor
Tirzepatide activates the GLP-1 receptor, so it belongs to the GLP-1 family in everyday usage. It also activates a second receptor, GIP, which separates it from semaglutide and every earlier drug in the class.
GIP stands for glucose-dependent insulinotropic polypeptide, GLP-1 for glucagon-like peptide-1. Both are incretins, gut hormones released after eating that prompt insulin release and signal to the brain that you have had enough.
Semaglutide hits one of those receptors. Tirzepatide hits both. That is all "dual agonist" means: one molecule activating two receptor targets instead of one.
The Zepbound prescribing information notes both receptors sit in brain regions involved in appetite regulation, and that nonclinical work suggests GIP may add to the regulation of food intake. See also how GLP-1 works.
Is Tirzepatide a Peptide?
Yes. Tirzepatide is a synthetic peptide, a chain of amino acids built on the native GIP sequence with engineered modifications.
One matters practically. A C20 fatty diacid chain binds the molecule to albumin in the blood, stretching its half-life to roughly five days. That is why tirzepatide is a weekly injection rather than a daily one.
Being a peptide is also why it cannot simply be swallowed: peptides are broken down in the digestive tract. That fact explains most of the confusion around tirzepatide pills.
Why "Dual Agonist" Is More Than a Marketing Word
The claim was tested head to head. SURPASS-2, an open-label 40-week phase 3 trial, randomized 1,879 adults with type 2 diabetes to tirzepatide at 5, 10 or 15 mg, or semaglutide 1 mg, all weekly with metformin.
In the published results, tirzepatide was noninferior and superior to semaglutide on the primary endpoint of HbA1c change. Weight reduction was greater too, with estimated treatment differences of 1.9 kg, 3.6 kg and 5.5 kg across the three doses.
Those are trial averages in a diabetes population, not a forecast for any individual. It is also dose-specific: semaglutide 1 mg is a diabetes dose, not the higher weight-management dose. Detail sits in tirzepatide vs semaglutide and the compounded comparison.
If the dual mechanism sounds like a fit for what you are dealing with, the next step is a written intake reviewed by a licensed provider. No appointment, and approval is never guaranteed.
See tirzepatide at Telos RxWhat SURMOUNT-1 Reported
SURMOUNT-1 is the trial most people are indirectly quoting when they discuss tirzepatide weight loss: a 72-week, double-blind, randomized, placebo-controlled phase 3 trial in 2,539 adults with obesity, or overweight plus a weight-related complication, excluding diabetes.
At week 72, the reported mean change in body weight was 15.0 percent with 5 mg weekly, 19.5 percent with 10 mg and 20.9 percent with 15 mg, against 3.1 percent with placebo.
These are averages from a controlled trial with a 20-week escalation period and structured support. They describe what the study found, not what any reader will experience.
Beyond Weight: The Sleep Apnea Indication
Zepbound's 2024 sleep apnea approval came from SURMOUNT-OSA, two 52-week trials measuring the apnea-hypopnea index rather than the scale. It establishes tirzepatide as a treatment for a specific condition, not only a weight number. Detail sits in tirzepatide for sleep apnea, benefits beyond weight loss and cardiovascular outcomes research.
Compounded Tirzepatide Is Not Mounjaro or Zepbound
This is the distinction most articles blur, and it matters clinically.
- Compounded tirzepatide is not FDA-approved. It has not been through the agency's own review of safety and effectiveness.
- It is prepared by licensed US compounding pharmacies under federal compounding regulations, against a prescription for an individual patient.
- It need not match a brand's concentration or device, so a vial and syringe is common where the brand uses a pen.
- It is not a supplement, and needs a licensed pharmacy.
Pen-versus-vial practicalities are in pens vs vials, the money side in tirzepatide cost, and vetting in how to get tirzepatide online safely.
Injection, Oral, Sublingual and Microdosed
Weekly subcutaneous injection is the form every pivotal trial used and the only form the approved brands come in. Compounded preparations come in other formats, which carry less evidence, not more.
There is no FDA-approved tirzepatide pill. The oral GLP-1 pill approved in 2026 is orforglipron, brand name Foundayo, a different molecule entirely. Compounded oral tirzepatide and sublingual preparations exist, but are not the approved brands in tablet form. See tirzepatide pills and oral tirzepatide.
Microdosed tirzepatide means deliberately staying below standard label doses, usually for tolerability. It is a prescribing approach rather than an approved regimen, and the research base is thin. See the microdosing schedule guide.
How Tirzepatide Is Dosed on the Label
The Zepbound prescribing information specifies a starting dose of 2.5 mg injected subcutaneously once weekly for four weeks, then increases in 2.5 mg steps at intervals of at least four weeks. The maximum recommended dose is 15 mg weekly.
The slow ramp exists because gastrointestinal side effects cluster during escalation. These figures describe the label, not instructions for you. Your provider decides the schedule. See the titration guide and how to inject tirzepatide.
Who Tirzepatide Is Not For
Tirzepatide carries a boxed warning for thyroid C-cell tumors, which occurred in rats. Whether that translates to humans is unknown, but the label is explicit: it is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2.
The most common adverse reactions are gastrointestinal and typically worst during titration. Less common but serious concerns include pancreatitis and gallbladder disease. It is not for use in pregnancy, and because it delays gastric emptying it can affect absorption of oral medications including oral contraceptives.
See tirzepatide side effects and nausea management research.
What a Provider Evaluation Involves
Telos Rx is an online-first, asynchronous, LegitScript-certified telehealth service. You complete a written intake covering health history, current medications, thyroid and pancreatic history and your goals. A licensed provider reviews it and responds in writing, often within hours, no appointment.
Everything is subject to medical approval by a licensed provider, and approval is not guaranteed. As of publication the tirzepatide page lists compounded tirzepatide as low as $139 per month, with flat pricing that does not rise as your dose is titrated, free 48-hour shipping if approved, FSA and HSA accepted, and cancellation any time. More in compounded tirzepatide via telehealth.
Keep Reading
Frequently Asked Questions
What is tirzepatide used for?
As the FDA-approved brands, tirzepatide is used for type 2 diabetes under Mounjaro and for chronic weight management under Zepbound, which also carries an approval for moderate-to-severe obstructive sleep apnea in adults with obesity. Compounded tirzepatide is not FDA-approved and is prescribed individually after a licensed provider reviews your health history.
Is tirzepatide a GLP-1?
Tirzepatide activates the GLP-1 receptor, so it is usually grouped with GLP-1 medications. It also activates a second receptor, GIP, which semaglutide does not. That is why it is described as a dual GIP and GLP-1 receptor agonist rather than a plain GLP-1 receptor agonist.
Is tirzepatide the same as Mounjaro or Zepbound?
Tirzepatide is the molecule inside both. Mounjaro is the brand approved for type 2 diabetes and Zepbound is the brand approved for chronic weight management and obstructive sleep apnea. Compounded tirzepatide contains the same active molecule but is not FDA-approved, and its concentration and presentation can differ from the brands.
Is tirzepatide a peptide?
Yes. Tirzepatide is a synthetic peptide built on the native GIP amino acid sequence with engineered modifications, including a fatty diacid chain that binds albumin and extends its half-life to about five days. That long half-life is what makes once-weekly dosing possible instead of daily dosing.
Is there a tirzepatide pill?
There is no FDA-approved tirzepatide pill. The oral GLP-1 tablet approved in 2026 is orforglipron, sold as Foundayo, and it is a different molecule entirely. Compounded oral and sublingual tirzepatide preparations exist but are not FDA-approved and are not the approved brands in tablet form.
Who should not take tirzepatide?
The label contraindicates it in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, because of a boxed warning for thyroid C-cell tumors in rodents. It is not for use in pregnancy. Pancreatitis, gallbladder and kidney history are all part of the provider review.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Ready to find out whether tirzepatide is a reasonable fit for you? Start with the tirzepatide product page, then complete the written intake at start.telosrx.com. A licensed provider reviews every request, and approval is not guaranteed.